Bristol-Myers Squibb and Pfizer have announced that the National Institute for Health and Care Excellence (NICE) has published final guidance recommending the use of Eliquis (apixaban) as an option for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. As part of the 90-day implementation plan, the National Health Service (NHS) now has three months for apixaban to be made available to patients in England and Wales whose doctors believe it is a clinically appropriate treatment for them.
ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--Cardiovascular Systems, Inc. (CSII) (CSI), announced today that it has received FDA clearance for the new 4 French (4 Fr) 1.25 Solid Diamondback 360® Peripheral Orbital Atherectomy System (OAS) for the treatment of peripheral artery disease (PAD).
LOWELL, Mass.--(Healthcare Sales & Marketing Network)--Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions, announced that the Alcyone MEMS Cannula (AMC™), a neuro-ventricular cannula, has received FDA clearance. The AMC is a dual-lumen, MRI-compatible injection and aspiration cannula for use in the brain. The AMC is not intended for implant, and it is intended for single patient use only.
BALTIMORE, April 23, 2015 -- (Healthcare Sales & Marketing Network) -- Clear Guide Medical announces that its first clinical product, the Clear Guide ONE, has received the CE Mark from its Notified Body. The CE Mark allows the marketing and sale of the medical device in 28 Member States of the European Union, as well as Iceland, Norway, Liechtenstein, Switzerland and Turkey.
WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the publication of the first clinical experience with supporting preclinical data in the Journal of the American College of Cardiology: Cardiovascular Interventions.
TEWKSBURY, Mass.--(Healthcare Sales & Marketing Network)--Mitralign today highlighted a presentation by Prof. Dr. med. J. Schofer of the Medicare Center and Department for Percutaneous Interventions of Structural Heart Disease, Albertinen Heart Center, Hamburg at the recent American College of Cardiology (ACC) Scientific Sessions detailing his experience with the Mitralign Transcatheter Annuloplasty System. At ACC, Schofer discussed his successful use of the Mitralign System to perform a direct transcatheter annuloplasty on special access patients with tricuspid regurgitation (TR). The Mitralign system is not approved for sale or distribution however, it is currently being evaluated in clinical trials for an indication in functional mitral regurgitation.
MARLBOROUGH, Mass. and MOUNTAIN VIEW, Calif., April 1, 2015 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device company that develops, manufactures and sells minimally invasive devices for Endoscopic Ultrasound (EUS) guided transluminal drainage of targeted areas within the gastrointestinal tract. The deal is expected to close this week.
BOSTON, April 15, 2015 -- (Healthcare Sales & Marketing Network) -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in stent embolic protection systems ("EPS"), today announced the completion of its sales restructuring program which began on January 4, 2015. The restructuring was implemented to conserve capital and to align the organization to a new commercial strategy built on third party distribution partners. Reflecting some impact from the transition, as well as the trend towards drug eluting stent use in STEMI patients discussed during our fourth quarter 2014 earnings call last month, total revenues for the first quarter 2015 were approximately $500,000, down sequentially from $850,000 in the fourth quarter 2014.
AngioDynamics has announced a worldwide licensing agreement with privately-held EmboMedics of Minneapolis, USA, which develops injectable and resorbable microspheres. Embolization is the fastest growing segment in interventional radiology, and this newly formed strategic relationship will allow AngioDynamics to leverage the talent and knowledge of its sales team to re-enter the approximately US$150 million addressable global embolic market.
Medtronic has launched the Fortrex over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. Fortrex utilises a high pressure balloon to break up the blockages and open the vessels to help maintain arteriovenous access in the peripheral vascular system.
BTG has announced the treatment of the first patient in Singapore with TheraSphere, a treatment for primary liver cancer and metastatic colorectal cancer, specifically engineered to deliver powerful doses of radiation to the tumour while minimising exposure to normal tissue in a procedure called radioembolization.
A study presented at the Society of Interventional Radiology’s (SIR’s) 2015 annual scientific meeting reveals that a new angiographic imaging platform (AlluraClarity, Philips Healthcare) maintains similar procedure time as a current C-arm imaging platform (Allura, Philips), yet with substantially reduced radiation exposure for uterine artery embolization procedures.
Researchers from Stanford University have created a mobile application to allow rapid identification of all inferior vena cava filter types and related complications. This scrollable app can be used to optimise care of patients with inferior vena cava filters, especially those with indwelling filters, they say. The app can run on Apple (iOS) and Google (Android) platforms and is ready for public launch.
A study from Institut Bergoniè (Bordeaux, France), in collaboration with Università Campus Bio-Medico di Roma (Rome, Italy), that set out to compare the duration of targeting and positioning of radiofrequency ablation electrode on lung tumours using two different modalities finds that cone-beam CT is faster than CT.
The study design and initial 30-day safety data of the BEAT Obesity (Bariatric embolization of arteries for the treatment of obesity) study were presented at the SIR annual scientific meeting in Atlanta.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos